Let’s face it, when it comes to cannabis stocks, Canada continues to crush the United States, where federal illegality makes it more difficult to operate and to raise capital....
CanniMed Therapeutics Inc. Reports Financial Results for Q1 2017 March 16, 2017 SASKATOON, Saskatchewan–(BUSINESS WIRE)–CanniMed Therapeutics Inc. (“CanniMed” or the “Company”) (TSX: CMED) (OTC: CMMDF) today released its financial...
CanniMed Therapeutics Inc. and PharmaChoice Enter into Canada’s First Exclusive Pharmacy Distribution Agreement for Medical Cannabis March 02, 2017 SASKATOON, Saskatchewan–(BUSINESS WIRE)–CanniMed Therapeutics Inc. (TSX:CMED) (OTC: CMMDF) (“CanniMed”) and...
After a boom in the stock prices of Canadian licensed producers (LPs) in 2016 that left the average stock up more than 355%, the sector is performing very well...
Trial Underway to Provide Scientific Validity of the Analgesic Efficacy and Safety of Medical Cannabis in an Experimental Autoimmune Encephalomyelitis (EAE) Animal Model of Multiple Sclerosis (MS)-Induced Neuropathic Pain...
Statement from Health Canada on the Testing of Cannabis for Medical Purposes for Unauthorized Pest Control Products OTTAWA, Feb. 7, 2017 /CNW/ – Recently, two licensed producers of cannabis...
CanniMed Therapeutics Inc. Provides Update on Patient Growth Rates, Sales Volume and Product Supply SASKATOON, Saskatchewan–(BUSINESS WIRE)–CanniMed Therapeutics Inc. (TSX:CMED) (“CMED” or the “Company”), a leading plant biopharmaceutical company...
Last week, James West of the Midas Letter published interviews of four CEOs of publicly-traded Canadian licensed producers, including Vic Neufeld of Aphria (TSXV: APH) (OTC: APHQF), Brent Zettl of...
Early trading in CanniMed Therapeutics (TSX: CMED) was disappointing, as the recent IPO broke its $12 offering price and traded below the $11.28 underwriters price. In the first half-hour...
Perhaps the biggest story of 2016 in the cannabis capital markets was the surge in prices and the amount of capital raised for the cannabis industry in Canada during...
CanniMed Therapeutics (TSX: CMED) priced its initial public offering at $12, selling 5mm shares through a syndicate led by AltaCorp Capital to raise $60mm. The underwriters, which also included Canaccord...
Canada’s Task Force on Cannabis Legalization and Regulation published its long-awaited report today. The report, delivered to Jody Wilson-Raybould, Minister of Justice and Attorney General of Canada, Jane Philpott,...
The list of Canadian licensed producers (LPs) of cannabis expecting to go public just got longer. CanniMed Therapeutics, the parent of CanniMed Ltd. and Prairie Plant Systems, issued a press...
The Economist explores the opportunity for Canada to legalize cannabis for adult use, extending upon its current medical cannabis program. It concludes: The existence of companies like Tweed, which obtained...
Brent Zettl, President of Prairie Plant Systems Inc. It’s not that Brent Zettl thinks there’s no place for a medical marijuana dispensary in Saskatoon. It just shouldn’t be dispensing marijuana....
